Development of lornoxicam multiparticulate sustained release drug delivery system using copal gum-pectin and optimization by applying central composite design

The purpose of the present study was to explore the scope of natural gum to control the drug releases and develop multiparticulate sustained drug delivery system for lornoxicam. Lornoxicam pellets were prepared using copal gum and pectin as natural release retarding polymers by extrusion and spheronization. A central composite design was employed as copal gum (X1) and pectin (X2) independent variables to optimize the lornoxicam pellets in terms of sustained release, production yield, sphericity, and flowability. The response (Y1) as percentage drug releases at 10 h, (Y2) time (t50) required to 50% drug release, (Y3) % yield and (Y4) average pellets size were measured for each trial and statistical equations with significant interaction terms were derived to predict relation. All the batches have excellent flow properties with angle of repose in the range of 11.57±0.33° to 15.94±0.84°, and carr’s index and hausner’s ratio in the range of 10.17±1.34% to 15.97±1.62% and 1.11±0.04 to 1.19±0.09, respectively. The drug release studies indicated that as the concentrations of polymers increases the drug release decreases, producing sustained release of lornoxicam. Among the multiparticulate batches, batch F7 was found to be optimized based on the criteria of attaining the minimum particle size (

PDF

___

[1] Patel PB, Dhake AS. Multiparticulate approach: an emerging trend in colon specific drug delivery for Chronotherapy. J Appl Pharm Sci. 2011; 1(5): 59-63.
[2] Schwartz JB, Connor RE, Schnaare RL. Optimization techniques in pharmaceutical formulation and processing. Modern pharmaceutics. CRC Press, 2002, pp. 921-950.
[3] Sivasankar M, Krishna M, Sunitha R. Formulation, evaluation and optimization of sustained release microcapsules of lornoxicam prepared with gum dikamali and pectin extracted from Dillenia Indica. Int J Chem Sci. 2015; 13(1): 97- 106.
[4] Ulla SN, Roy AK, Kulkarni M, Kumar SM. Formulation and evaluation of sustained release matrix tablets of lornoxicam. Int J Drug Dev Res. 2011; 1(3): 31-44.
[5] Basak N, Aksoy Y, Kaydu A, Sahin OF. Lornoxicam use to reduce the pain associated with propofol injection. Libyan J Med. 2017; 12(1): 1313093. [CrossRef]
[6] Kalyanappa S, Krishna MR, Goli D. Design and in-vitro evaluation of a novel sustained release double layered tablets of lornoxicam by using semi synthetic polymers. Indian J Pharm Educ. 2015; 49(4): 281-291. [CrossRef]
[7] Hamza YE, Aburahma MH. Design and in-vitro evaluation of novel sustained-release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers. Pharm Dev Technol. 2010; 15(2): 139-153. [CrossRef]
[8] Pagar R, Patil D, Pawar P, Ghule RS, Bairagi VA. Formulation and development of sustained release matrix tablets of lornoxicam. J Drug Deliv Ther. 2018; 8(2): 102-106. [CrossRef]
[9] Gupta MM, Ray B. A review on sustained release technology. Int J Ther Appl. 2012; 8: 1-23.
[10] Hamza YE, Aburahma MH. Design and in-vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination. AAPS PharmSciTech. 2009; 10(4): 1357. [CrossRef]
[11] Mehta KA, Kislaloglu MS, Phuapradit W. Release performance of poorly soluble drug from a novel Eudragit based multi-unit erosion matrix. Int J Pharm. 2001; 213: 7-12. [CrossRef]
[12] Korsmeyer R, Gurny R, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983; 15: 25-35. [CrossRef]
[13] Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, Dickinson PA, Dressman J, Holm R, Klein S, Mann J. In-vitro models for the prediction of in-vivo performance of oral dosage forms. Eur J Pharm Sci. 2014; 57: 342-366. [CrossRef]
[14] Shende MA, Marathe RP. Development and optimization of oral gastroadhesive matrices for diltiazem hydrochloride using some natural materials. Res J Pharm Technol. 2016; 9(7): 817-830. [CrossRef]
[15] Singh G, Pai RS, Devi VK. Response surface methodology and process optimization of sustained release pellets using Taguchi orthogonal array design and central composite design. J Adv Pharm Technol Res. 2012; 3(1): 30. [CrossRef]
[16] Lavanya K, Senthil V, Rathi V. Pelletization technology: a quick review. Int J Pharm Sci Res. 2011; 2(6): 1337-1355.
[17] Morkhade DM, Fulzele SV, Satturwar PM, Joshi SB. Gum copal and gum damar: novel matrix forming materials for sustained drug delivery. Indian J Pharm Sci. 2006; 68(1): 53-58. [CrossRef]
[18] Pagariya TP, Patil SB. Development and optimization of multiparticulate drug delivery system of alfuzosin hydrochloride. Colloids Surf B. 2013; 102: 171-177. [CrossRef]
[19] Tubati VP. Formulation development and statistical optimization of ivabradine hydrochloride floating pulsatile microspheres using response surface methodology. Asian J Pharm. 2016; 10(2): 1-11.
[20] Patil SM, Mishra RV, Shirolkar SV. Development and evaluation of sustain release simvastatin pellets. Res J Pharm Technol. 2017; 10(8): 2467-2473. [CrossRef]
[21] Gonullu U, Gurpınar P, Uner M. Double-layer tablets of lornoxicam: validation of quantification method, in-vitro dissolution and kinetic modelling. Trop J Pharm Res. 2015; 14(9): 1659-1666.
[22] ICH Topic Q1A (R2): Note for guidance on stability testing: stability testing of new drug substances and products. 2003; CPMP/ICH/2736/99. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf (accessed on 18 July 2018).